Physician profile
Eric L Woolley
NPI 1205230414
$4,390.50
in general payments reported to CMS, 2019-2025
17 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.48 · 2020: $160 · 2021: $126 · 2022: $1,325 · 2023: $1,383 · 2024: $1,186 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,386 · Food and Beverage: $921 · Long Term Medical Supply Or Device Loan: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,385.79 |
| Food and Beverage | $920.99 |
| Long Term Medical Supply Or Device Loan | $386.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paragon 28, INC. | $2,000.03 | 2021-2024 | Portfolio, Hammertube Sterile Implant Kits, Precision Mis Bunion |
| Conetic Solutions, INC. | $1,221.44 | 2022 | |
| Integra Lifesciences Corporation | $561.36 | 2019-2025 | Acell, Integra, Integra Dermal Regeneration Template |
| Smith+Nephew, INC. | $236.46 | 2019-2025 | Grafix Pl, Grafix, Oasis |
| Shockwave Medical, INC | $58.39 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Stryker Corporation | $54.76 | 2022-2023 | Aequalis Perform |
| Depuy Synthes Sales INC. | $42.50 | 2019 | |
| Solventum Corporation | $42.01 | 2025 | 3m Cavilon, Prevena, V.A.C. Veraflo Cleanse Choice |
| Organogenesis INC. | $30.12 | 2023 | Puraply |
| Hartmann USA, INC. | $28.56 | 2023 | Zetuvit Plus |
| Polynovo North America LLC | $23.86 | 2025 | Novosorb Btm |
| Grt US Holding, INC. | $20.65 | 2022 | |
| Averitas Pharma INC. | $15.68 | 2024 | Qutenza |
| Kerecis Limited | $14.71 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.51 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $13.25 | 2024 | Opsumit, Uptravi |
| Eisai INC. | $12.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Woolley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.